Ballard Spahr Advises Spark Therapeutics in Licensing Agreement for Investigational Gene Therapy for Epilepsy
Attorneys from Ballard Spahr advised Spark Therapeutics (Spark) in the company’s exclusive collaboration and licensing agreement with CombiGene AB (CombiGene), a Swedish gene therapy development company, for CombiGene’s CG01 project, an investigational gene therapy that aims to treat drug-resistant focal epilepsy.
Spark recently announced the agreement.
The Ballard Spahr team was led by Brian D. Doerner, co-practice leader of the firm’s Mergers and Acquisitions Group, and included Group members Sandra M. Wintner and Christian R. Barnes.
They advised Spark on the agreement, which provides Spark with the exclusive, worldwide license to develop, manufacture, and commercialize CG01. CombiGene will continue to execute certain aspects of the preclinical program in collaboration with Spark. CG01 is a unique gene therapy candidate aimed at a large patient population to solve a global need in epilepsy treatment. CG01 is in a late preclinical stage.
Spark, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), is a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease.
For media inquiries, please contact Bill Shralow at 215.864.8195.